17,115 Shares in AbbVie Inc. $ABBV Purchased by Mmbg Investment Advisors CO.

Posted by Geri Gentry on Aug 30th, 2026

Mmbg Investment Advisors CO. purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,115 shares of the company’s stock, valued at approximately $4,307,000.

Several other large investors have also recently added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie during the fourth quarter worth about $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the period. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the fourth quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID grew its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, Marquette Asset Management LLC raised its position in shares of AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease
Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. BNP Paribas Exane increased their target price on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.95.

Check Out Our Latest Analysis on AbbVie

AbbVie Trading Down 0.8%

AbbVie stock opened at $256.08 on Friday. The stock has a market cap of $452.44 billion, a price-to-earnings ratio of 72.34, a PEG ratio of 0.85 and a beta of 0.30. The company’s 50-day moving average price is $252.66 and its two-hundred day moving average price is $228.87. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.